How common are myeloproliferative neoplasms? A systematic review and meta-analysis

G.J. Titmarsh, A.S. Duncombe, M.F. Mcmullin, M. O'Rorke, R. Mesa, F. De Vocht, S. Horan, Lin Fritschi, M. Clarke, L.A. Anderson

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P=0.007 and P≤0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. © 2014 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)581-587
JournalAmerican Journal of Hematology
Volume89
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Primary Myelofibrosis
Meta-Analysis
Essential Thrombocythemia
Incidence
Polycythemia Vera
Neoplasms
Publication Bias
PubMed
MEDLINE
Databases

Cite this

Titmarsh, G. J., Duncombe, A. S., Mcmullin, M. F., O'Rorke, M., Mesa, R., De Vocht, F., ... Anderson, L. A. (2014). How common are myeloproliferative neoplasms? A systematic review and meta-analysis. American Journal of Hematology, 89(6), 581-587. https://doi.org/10.1002/ajh.23690
Titmarsh, G.J. ; Duncombe, A.S. ; Mcmullin, M.F. ; O'Rorke, M. ; Mesa, R. ; De Vocht, F. ; Horan, S. ; Fritschi, Lin ; Clarke, M. ; Anderson, L.A. / How common are myeloproliferative neoplasms? A systematic review and meta-analysis. In: American Journal of Hematology. 2014 ; Vol. 89, No. 6. pp. 581-587.
@article{9bd365db2dec4c49bc008ec3fd0c9562,
title = "How common are myeloproliferative neoplasms? A systematic review and meta-analysis",
abstract = "Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1-99.8{\%}) and evidence of publication bias for ET and PMF (Egger test, P=0.007 and P≤0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. {\circledC} 2014 Wiley Periodicals, Inc.",
author = "G.J. Titmarsh and A.S. Duncombe and M.F. Mcmullin and M. O'Rorke and R. Mesa and {De Vocht}, F. and S. Horan and Lin Fritschi and M. Clarke and L.A. Anderson",
year = "2014",
doi = "10.1002/ajh.23690",
language = "English",
volume = "89",
pages = "581--587",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "John Wiley & Sons",
number = "6",

}

Titmarsh, GJ, Duncombe, AS, Mcmullin, MF, O'Rorke, M, Mesa, R, De Vocht, F, Horan, S, Fritschi, L, Clarke, M & Anderson, LA 2014, 'How common are myeloproliferative neoplasms? A systematic review and meta-analysis' American Journal of Hematology, vol. 89, no. 6, pp. 581-587. https://doi.org/10.1002/ajh.23690

How common are myeloproliferative neoplasms? A systematic review and meta-analysis. / Titmarsh, G.J.; Duncombe, A.S.; Mcmullin, M.F.; O'Rorke, M.; Mesa, R.; De Vocht, F.; Horan, S.; Fritschi, Lin; Clarke, M.; Anderson, L.A.

In: American Journal of Hematology, Vol. 89, No. 6, 2014, p. 581-587.

Research output: Contribution to journalArticle

TY - JOUR

T1 - How common are myeloproliferative neoplasms? A systematic review and meta-analysis

AU - Titmarsh, G.J.

AU - Duncombe, A.S.

AU - Mcmullin, M.F.

AU - O'Rorke, M.

AU - Mesa, R.

AU - De Vocht, F.

AU - Horan, S.

AU - Fritschi, Lin

AU - Clarke, M.

AU - Anderson, L.A.

PY - 2014

Y1 - 2014

N2 - Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P=0.007 and P≤0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. © 2014 Wiley Periodicals, Inc.

AB - Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta-analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty-four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1-99.8%) and evidence of publication bias for ET and PMF (Egger test, P=0.007 and P≤0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. © 2014 Wiley Periodicals, Inc.

U2 - 10.1002/ajh.23690

DO - 10.1002/ajh.23690

M3 - Article

VL - 89

SP - 581

EP - 587

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 6

ER -

Titmarsh GJ, Duncombe AS, Mcmullin MF, O'Rorke M, Mesa R, De Vocht F et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. American Journal of Hematology. 2014;89(6):581-587. https://doi.org/10.1002/ajh.23690